Moderna partners with Takeda, Japanese government on additional 50 million COVID-19 vaccine dosesMarket Watch • 07/20/21
Moderna Partners with Takeda and the Government of Japan to Supply Additional 50 Million Doses of Moderna's COVID-19 Vaccine and Variant Booster Vaccine Candidate in 2022Business Wire • 07/20/21
New Data from the Phase 3 HELP Study™ Open-Label Extension Evaluating Safety and Efficacy of TAKHZYRO® (lanadelumab) for Hereditary Angioedema Patients to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid CongressBusiness Wire • 07/10/21
European Patient Survey finds Crohn's Disease Patients Living with Perianal Fistulas Experience a More Significant Negative Impact on Their Quality of Life than Crohn's Disease Patients without Perianal FistulasBusiness Wire • 07/09/21
Takeda Announces the Publication of Its Annual Report on Form 20-F for FY2020Business Wire • 06/29/21
Takeda introduces the In Their Shoes experience to the Middle East in support of the IBD patient communityPRNewsWire • 06/09/21
Phase 3 Clinical Trial Subgroup Analysis Across Solid Organ Transplant (SOT) Types Supports Efficacy of Maribavir Over Conventional Therapies in Post-Transplant Recipients With Cytomegalovirus (CMV) Infection (Refractory, With or Without Resistance)Business Wire • 06/07/21
Takeda's Dengue Vaccine Effective In Reducing Hospitalization Regardless Of Prior InfectionBenzinga • 05/24/21
Potential Impact of Takeda's Dengue Vaccine Candidate Reinforced by Long-Term Safety and Efficacy ResultsBusiness Wire • 05/22/21
U.S. Food & Drug Administration Grants Priority Review of Maribavir for the Treatment of Post-Transplant Recipients With Cytomegalovirus Infection in Those Resistant and/or Refractory to Prior Anti-CMV TreatmentBusiness Wire • 05/21/21
Takeda to Present Positive Primary Analysis from Phase 2 OPTIC Trial of ICLUSIG® (ponatinib), Reinforcing Ability to Address Gaps in Care for Chronic-Phase CMLBusiness Wire • 05/19/21
Takeda Presents Updated Results for Mobocertinib, Further Substantiating the Clinical Benefit in Patients with EGFR Exon20 Insertion+ mNSCLCBusiness Wire • 05/19/21
Takeda Pharmaceutical Company Limited's (TAK) CEO Christophe Weber on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/11/21
Takeda says it may double imports of Moderna shots to help accelerate Japan vaccinationReuters • 05/11/21
Takeda Delivers Resilient FY2020 Results With Strong Margins & Robust Cashflow; Underlying Revenue Growth Expected to Accelerate in FY2021Business Wire • 05/11/21
